Prestige Wealth Management Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.37M | Buy |
17,347
+26
| +0.2% | +$5.59K | 0.79% | 28 |
|
|
2026
Q1 | $3.77M | Sell |
17,321
-65
| -0.4% | -$14.4K | 0.74% | 29 |
|
|
2025
Q4 | $3.97M | Buy |
17,386
+5,190
| +43% | +$1.18M | 0.76% | 27 |
|
|
2025
Q3 | $2.82M | Buy |
12,196
+7,596
| +165% | +$1.55M | 0.54% | 35 |
|
|
2025
Q2 | $854K | Buy |
4,600
+133
| +3% | +$24.7K | 0.17% | 65 |
|
|
2025
Q1 | $936K | Buy |
4,467
+99
| +2% | +$19.2K | 0.2% | 62 |
|
|
2024
Q4 | $776K | Buy |
4,368
+245
| +6% | +$45K | 0.16% | 71 |
|
|
2024
Q3 | $814K | Buy |
4,123
+384
| +10% | +$71.7K | 0.17% | 70 |
|
|
2024
Q2 | $641K | Buy |
3,739
+3,094
| +480% | +$513K | 0.14% | 73 |
|
|
2024
Q1 | $117K | Sell |
645
-268
| -29% | -$46.2K | 0.03% | 188 |
|
|
2023
Q4 | $141K | Sell |
913
-84
| -8% | -$12.2K | 0.03% | 161 |
|
|
2023
Q3 | $149K | Sell |
997
-42
| -4% | -$6.17K | 0.04% | 154 |
|
|
2023
Q2 | $140K | Sell |
1,039
-4,950
| -83% | -$726K | 0.03% | 176 |
|
|
2023
Q1 | $954K | Buy |
5,989
+4,798
| +403% | +$734K | 0.24% | 51 |
|
|
2022
Q4 | $192K | Sell |
1,191
-4,211
| -78% | -$646K | 0.05% | 138 |
|
|
2022
Q3 | $725K | Buy |
5,402
+494
| +10% | +$70.9K | 0.2% | 53 |
|
|
2022
Q2 | $751K | Buy |
4,908
+228
| +5% | +$34.8K | 0.2% | 52 |
|
|
2022
Q1 | $759K | Buy |
4,680
+3,487
| +292% | +$507K | 0.19% | 62 |
|
|
2021
Q4 | $161K | Buy |
1,193
+16
| +1% | +$1.89K | 0.04% | 158 |
|
|
2021
Q3 | $127K | Buy |
1,177
+629
| +115% | +$71.9K | 0.03% | 172 |
|
|
2021
Q2 | $61K | Hold |
548
| – | – | 0.02% | 229 |
|
|
2021
Q1 | $60K | Buy |
548
+6
| +1% | +$642 | 0.02% | 231 |
|
|
2020
Q4 | $58K | Buy |
542
+181
| +50% | +$17.4K | 0.02% | 232 |
|
|
2020
Q3 | $32K | Hold |
361
| – | – | 0.01% | 297 |
|
|
2020
Q2 | $36K | Sell |
361
-1,411
| -80% | -$124K | 0.01% | 261 |
|
|
2020
Q1 | $135K | Buy |
1,772
+196
| +12% | +$16.7K | 0.06% | 99 |
|
|
2019
Q4 | $140K | Buy |
1,576
+124
| +9% | +$10.3K | 0.08% | 137 |
|
|
2019
Q3 | $110K | Hold |
1,452
| – | – | 0.06% | 143 |
|
|
2019
Q2 | $105K | Buy |
1,452
+17
| +1% | +$1.34K | 0.06% | 151 |
|
|
2019
Q1 | $115K | Buy |
1,435
+950
| +196% | +$77.7K | 0.07% | 135 |
|
|
2018
Q4 | $45K | Buy |
+485
| New | +$42.7K | 0.03% | 204 |
|
Other funds holding ABBV
Prestige Wealth Management Group's ABBV Position: Q2 2026 in Review
Prestige Wealth Management Group increased its AbbVie (ABBV) stake by 0.15% in Q2 2026, buying an estimated $5.59K and bringing the position to 17,347 shares worth $4.37M. The position accounts for 0.79% of the portfolio, ranked #28.
Prestige Wealth Management Group first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Prestige Wealth Management Group held 17,347 shares of AbbVie worth $4.37M as of Q2 2026.
- Prestige Wealth Management Group bought 26 AbbVie shares in Q2 2026, an estimated $5.59K.
- AbbVie made up 0.79% of Prestige Wealth Management Group's portfolio in Q2 2026, its #28 holding.
- Prestige Wealth Management Group first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.